Exelixis EXEL saw its IBD SmartSelect Composite Rating jump to 96 Wednesday, up from 94 the day before. The upgrade means the ...

We recently compiled a list of the Top 10 Oncology Stocks to Buy Now. Exelixis, Inc. is placed eighth among the best cancer ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common ...

Truist Financial analyst Asthika Goonewardene reiterated a Buy rating on Exelixis today and set a price target of $51.00. According to TipRanks, Goonewardene is an analyst with an average return of -3 ...

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report ...

Exelixis, Inc. EXEL reported preliminary, unaudited financial results for fiscal year 2025, issued financial guidance for ...

U.S. stock futures were lower this morning, with the Dow futures falling more than 300 points on Monday. Shares of Exelixis ...

Preliminary Fiscal Year 2025 Financial Results & 2026 Financial Guidance ...

Exelixis teamed with Natera on the phase III STELLAR-316 study testing zanzalintinib in resected stage II/III colorectal ...

If you are wondering whether Exelixis at around US$46.19 is offering fair value or a potential bargain, this article walks ...

Analysts' ratings for Exelixis (NASDAQ:EXEL) over the last quarter vary from bullish to bearish, as provided by 10 analysts.

Investing.com -- Exelixis Inc (NASDAQ:EXEL) stock rose 3.8% and Natera Inc (NASDAQ:NTRA) shares gained 1.6% Wednesday after ...